Exactech, Inc. (EXAC) Receives Consensus Recommendation of “Buy” from Brokerages
Shares of Exactech, Inc. (NASDAQ:EXAC) have earned a consensus broker rating score of 2.33 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a hold rating and one has issued a strong buy rating on the company. Exactech’s rating score has declined by 133% in the last three months as a result of various analysts’ ratings changes.
Brokers have set a 1 year consensus price target of $42.00 for the company and are expecting that the company will post $0.23 earnings per share for the current quarter, according to Zacks. Zacks has also given Exactech an industry rank of 160 out of 265 based on the ratings given to related companies.
Several equities research analysts recently commented on EXAC shares. Gabelli reiterated a “buy” rating on shares of Exactech in a research report on Monday, July 31st. Robert W. Baird set a $34.00 target price on shares of Exactech and gave the stock a “buy” rating in a research report on Sunday, October 15th. BidaskClub upgraded shares of Exactech from a “sell” rating to a “hold” rating in a research report on Friday, August 18th. Finally, Sidoti downgraded shares of Exactech from a “buy” rating to a “neutral” rating in a research report on Monday.
COPYRIGHT VIOLATION NOTICE: “Exactech, Inc. (EXAC) Receives Consensus Recommendation of “Buy” from Brokerages” was originally published by American Banking News and is the sole property of of American Banking News. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.americanbankingnews.com/2017/10/24/exactech-inc-exac-receives-consensus-recommendation-of-buy-from-brokerages.html.
In other news, Director Fern Watts sold 1,013 shares of the business’s stock in a transaction that occurred on Tuesday, August 8th. The shares were sold at an average price of $29.04, for a total value of $29,417.52. Following the transaction, the director now owns 4,727 shares in the company, valued at approximately $137,272.08. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 28.30% of the stock is currently owned by insiders.
Several large investors have recently added to or reduced their stakes in the company. Northpointe Capital LLC bought a new stake in shares of Exactech in the 3rd quarter valued at $5,102,000. The Manufacturers Life Insurance Company increased its stake in shares of Exactech by 3.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 9,323 shares of the medical equipment provider’s stock valued at $278,000 after acquiring an additional 289 shares in the last quarter. State Street Corp increased its stake in shares of Exactech by 7.5% in the 2nd quarter. State Street Corp now owns 207,721 shares of the medical equipment provider’s stock valued at $6,192,000 after acquiring an additional 14,537 shares in the last quarter. Numeric Investors LLC increased its stake in shares of Exactech by 4.4% in the 2nd quarter. Numeric Investors LLC now owns 30,643 shares of the medical equipment provider’s stock valued at $913,000 after acquiring an additional 1,300 shares in the last quarter. Finally, Voya Investment Management LLC bought a new stake in shares of Exactech in the 2nd quarter valued at $243,000. Institutional investors own 64.09% of the company’s stock.
Shares of Exactech (NASDAQ:EXAC) opened at 41.85 on Tuesday. Exactech has a 1-year low of $22.20 and a 1-year high of $42.55. The company’s 50 day moving average is $32.18 and its 200-day moving average is $30.28. The company has a market capitalization of $600.46 million, a P/E ratio of 804.81 and a beta of 1.01.
Exactech (NASDAQ:EXAC) last posted its earnings results on Thursday, July 27th. The medical equipment provider reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Exactech had a net margin of 0.30% and a return on equity of 7.39%. The business had revenue of $67.30 million for the quarter, compared to the consensus estimate of $67.75 million. During the same period last year, the company earned $0.31 EPS. The firm’s revenue was up 1.8% compared to the same quarter last year. On average, equities research analysts forecast that Exactech will post $1.29 EPS for the current year.
Exactech Company Profile
Exactech, Inc develops, manufactures, markets, distributes and sells orthopedic implant devices, related surgical instrumentation and biologic services to hospitals and physicians. The Company’s segments include knee, hip, biologics and spine, extremity and other products. Its other products segment includes miscellaneous sales categories, such as bone cement, instrument rental fees, shipping charges and other product lines.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Exactech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exactech Inc. and related companies with MarketBeat.com's FREE daily email newsletter.